Abstract: The invention relates to a method of treatment of collagenous connective tissue removed from a donor for implant into a recipient which is re-habited or re-colonized by host cells without an immune rejection and inflammatory reaction. After removal from the donor the tissue is trimmed and thereafter soaked in a cold stabilizing solution having a temperature range of 4 to 10 degrees centigrade. The tissue is then soaked at a predetermined temperature in a polyglycol, salt, hydrogen peroxide, and phosphate buffer first solution of predetermined quantities and concentrations and of sufficient ionic strength to permit ground substances to dissociate such that the collagen fibers remain stable. The tissue is then soaked in an alcohol and water solution at a predetermined temperature for a sufficient period of time to remove the residue of the first solution.
Abstract: The present invention aims to provide a substance(s), especially a peptide(s) capable of inhibiting the TGF-? activation reaction. The present invention provides a peptide consisting of 11 to 50 amino acid residues, which comprises an amino acid sequence Gln-Ile-Leu-Ser-X1-X2-X3-X4-Ala-Ser-Pro (SEQ ID NO: 1) wherein each of X1 to X4 independently represents any given amino acid residue, and X1-X2-X3-X4 is a sequence that is not Lys-Leu-Arg-Leu (SEQ ID NO: 12) and is not cleavable by proteases.
Abstract: The present invention relates to methods for preventing and treating Alzheimer's disease (AD). An A?42 mimotope is used for vaccination against AD. The mimotope induces the production of antibodies against A?42 but not against the native APP. The mimotope is functionally similar to, but not structurally identical with DAEFRH (SEQ ID NO: 1) which is a part of the naturally-occurring A?42 sequence.
Abstract: Compositions, methods, and kits for detecting and monitoring kinase, phosphatase and protein post-translational modification activity are described. The compositions typically include a peptide, a detectable moiety, and a protease cleavage site. Modification of a peptide by a kinase, phosphatase or other protein post-translational modification alters the proteolytic sensitivity of the peptide, resulting in a change of a detectable property of the composition. Panel assays for determining substrates or modulators of kinase, phosphatase or other protein post-translational modification activity are also described.
Type:
Grant
Filed:
July 14, 2006
Date of Patent:
June 1, 2010
Assignee:
Life Technologies Corporation
Inventors:
Tony A. Klink, Jane A. Beebe, David A. Lasky, Karen M. Kleman-Leyer, Richard Somberg
Abstract: The present invention provides novel Pancreatic Polypeptide Family (“PPF”) polypeptides and methods for their use.
Type:
Grant
Filed:
December 12, 2005
Date of Patent:
May 25, 2010
Assignee:
Amylin Pharmaceuticals, Inc.
Inventors:
Odile Esther Levy, Carolyn M. Jodka, Soumitra S. Ghosh, David G. Parkes, Richard A. Pittner, Lawrence J. D'Souza, John S. Ahn, Kathryn S. Prickett, Jonathan David Roth, Sean H. Adams
Abstract: Disclosed herein are polypeptide multilayer films comprising a hybrid polypeptide comprising a first polypeptide segment and a second segment, the two segments being covalently joined by one or more non-peptidic linkages. The first segment comprises a polypeptide having a magnitude of net charge per residue of greater than or equal to 0.4, and a length of greater than or equal to about 12 amino acid residues. The second segment comprises a polypeptide or another polyelectrolyte.
Abstract: A progesterone regulator capable of modulating the non-genomic action of progesterone and methods of using the progesterone regulator are described. The progesterone regulator is useful for attenuating progesterone's inhibition of apoptosis and for the treatment of patients having a progesterone-responsive tissue disease such as endometriosis or cancer, particularly ovarian cancer.
Abstract: The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis c virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis c virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
Type:
Grant
Filed:
November 20, 2006
Date of Patent:
May 18, 2010
Assignee:
Enanta Pharmaceuticals, Inc.
Inventors:
Zhenwei Miao, Ying Sun, Suanne Nakajima, Datong Tang, Zhe Wang, Yat Sun Or
Abstract: The present invention provides a composition and related methods for delivering cargo to a mitochondria which includes (a) a membrane active peptidyl fragment having a high affinity with the mitochondria and (b) cargo. The cargo may be selected from a wide variety of desired cargos which are to be delivered to the mitochondria for a specific purpose. Compositions and methods are disclosed for treating an illness that is caused or associated with cellular damage or dysfunction which is caused by excessive mitochondrial production of reaction oxygen species (ROS). Compositions which act as mitochondria-selective targeting agents using the structural signaling of the ?-turn recognizable by cells as mitochondria) targeting sequences are discussed. Mitochondria and cell death by way of apoptosis is inhibited as a result of the ROS-scavenging activity, thereby increasing the survival rate of the patient.
Type:
Grant
Filed:
December 1, 2006
Date of Patent:
May 18, 2010
Assignee:
University of Pittsburgh-Of the Commonwealth System of Higher Education
Inventors:
Peter Wipf, Jingbo Xiao, Mitchell P. Fink, Valerian E. Kagan, Yulia Y. Tyurina, Anthony J. Kanai
Abstract: Ready-to-use bivalirudin compositions, methods of using the ready-to-use bivalirudin compositions, and methods of preparing the ready-to-use bivalirudin compositions. The ready-to-use bivalirudin compositions comprise bivalirudin and one or more stabilizing agents. The one or more stabilizing agents may be buffering agents having a pKa of about 2.5 to about 6.5, pH-adjusting agents, polymers, preservatives, antioxidants, sugars or polyols, or a combination thereof. The ready-to-use bivalirudin compositions may also comprise [9-10]-cycloimido bivalirudin, [11-12]-cycloimido bivalirudin, or a combination thereof. The method of using the ready-to-use bivalirudin compositions comprises administering the ready-to-use compositions to a patient in need thereof. Further, the method of preparing the ready-to-use bivalirudin compositions comprises mixing bivalirudin with one or more stabilizing agents.
Type:
Grant
Filed:
September 21, 2009
Date of Patent:
May 11, 2010
Assignees:
The Medicines Company, Eagle Pharmaceuticals, Inc.
Abstract: The invention provides a self-assembling peptide comprising (a) a first amino acid domain that mediates self-assembly, wherein the domain comprises alternating hydrophobic and hydrophilic amino acids that are complementary and structurally compatible and self-assemble into a macroscopic structure when present in unmodified form; and (b) a second amino acid domain that does not self-assemble in isolated form. In certain embodiments of the invention the second amino acid domain comprises a biologically active peptide motif, e.g., a peptide motif found in a naturally occurring protein, or a target site for an interaction with a biomolecule. In certain embodiments of the invention the naturally occurring protein is a component of the extracellular matrix, e.g., a component of the basement membrane. The invention further provides scaffolds comprising the self-assembling peptides and methods of using the scaffolds including for cell culture, tissue engineering, and tissue repair.
Type:
Grant
Filed:
June 25, 2004
Date of Patent:
May 11, 2010
Assignee:
Massachusetts Institute of Technology
Inventors:
Elsa Genove, Shuguang Zhang, Carlos Semino
Abstract: This invention provides cross-linked glycopeptide-cephalosporin compounds and pharmaceutically acceptable salts thereof which are useful as antibiotics. This invention also provides pharmaceutical compositions containing such compounds; methods for treating bacterial infections in a mammal using such compounds; and processes and intermediates useful for preparing such compounds.
Type:
Grant
Filed:
August 24, 2007
Date of Patent:
May 11, 2010
Assignee:
Theravance, Inc.
Inventors:
Paul R. Fatheree, Martin S. Linsell, Daniel Marquess, S. Derek Turner
Abstract: The present invention relates to a method for preparing a peptide having a stable, internally constrained alpha-helical, beta-sheet/beta-turn, 310-helical, or pi-helical region and a method of stabilizing an alpha-helical, beta-sheet/beta-turn, 310-helical, or pi-helical region within a peptide structure. The resulting peptides and methods of using them are also disclosed.
Abstract: Disclosed herein are transmembrane transporter compounds containing guanidinium groups to enhance transport of a polymer backbone across biomembranes. Therapeutic and other biologically active moieties may be attached to the compounds. The polymer backbone may include peptide nucleic acid monomer units.
Type:
Grant
Filed:
September 21, 2006
Date of Patent:
April 20, 2010
Assignee:
Nitto Denko Corporation
Inventors:
Gang Zhao, Chieko Kitaura, Jian Liu, Lei Yu
Abstract: Combinatorially generated peptides are provided that have binding affinity for Polytetrafluoroethylene (PTFE). The peptides may be used to deliver benefit agents to various PTFE surfaces.
Type:
Grant
Filed:
December 1, 2006
Date of Patent:
April 20, 2010
Assignee:
E. I. du Pont de Nemours and Company
Inventors:
Scott D. Cunningham, David J. Lowe, John P. O'Brien, Hong Wang, Antoinette E. Wilkins
Abstract: A novel material having ice nucleation activity or activity to promote freezing is provided. The present invention related to a carrier upon which polypeptides are immobilized for promoting the freezing of water or a hydrous substance. That is a carrier upon which polypeptides having side chains for binding to water molecules on the molecular surfaces of the polypeptides are integrated and immobilized; and a carrier upon which antifreeze proteins are integrated and immobilized.
Type:
Grant
Filed:
December 7, 2006
Date of Patent:
April 20, 2010
Assignee:
National Institute of Advanced Industrial Science and Technology
Abstract: Compounds of the formula (I): and N-oxides, salts and stereoisomers thereof wherein A is OR1, NHS(?O)pR2, NHR3, NRaRb, C(?O)NHR3 or C(?O)NRaRb wherein; R1 is hydrogen, C1-C6alkyl, C0-C3alkylenecarbocyclyl, C0-C3alkyleneheterocyclyl; R2 is C1-C6alkyl, C0-C3alkylenecarbocyclyl, C0-C3alkyleneheterocyclyl or NRaRb; R3 is C1-C6alkyl, C0-C3alkylenecarbocyclyl, C0-C3alkyleneheterocyclyl, —OC1-C6alkyl, —OC0-C3alkylenecarbocyclyl, —OC0-C3alkyleneheterocyclyl; wherein any alkyl, carbocyclyl or heterocycylyl in R1, R2 or R3 are optionally substituted p is independently 1 or 2; n is 3, 4, 5 or 6; denotes an optional double bond; Rq is H or when L is CRz, Rq can also be C1-C6alkyl; Ry and Ry? are independently C1-C6alkyl; L is N or CRz; Rz is H or forms a double bond with the asterisked carbon; W is —CH2—, —O—, —OC(?O)NH—, —OC(?O)—, —S—, —NH—, —NRa, —NHS(?O)2—, —NHC(=0)NH— or —NHC(?O)—, —NHC(?S)NH— or a bond; R8 is an optionally substituted ring system containing 1 or 2 saturated, partially saturated or unsaturated carbo
Abstract: The present invention provides analogues of duocarmycins that are potent cytotoxins. Also provided are peptidyl and disulfide linkers that are cleaved in vivo. The linkers are of use in forming prodrugs and conjugates of the cytotoxins of the invention as well as other diagnostic and therapeutic moieties. The invention provides prodrugs and conjugates of the duocarmycin analogues with the linker arms of the invention.
Type:
Grant
Filed:
May 23, 2008
Date of Patent:
April 20, 2010
Assignee:
Medarex, Inc.
Inventors:
Howard P. Ng, Danny P. C. McGee, Guoxian Wu, Jimmie Moore, Zhi-Hong Li, Sanjeev Gangwar, Oliver L. Saunder, Irina Astafieva, Valeri Martichonok
Abstract: The present invention relates to novel cyclic or constrained acyclic compounds which modulate the activity of G protein-coupled receptors and are useful in the treatment of conditions mediated by G protein-coupled receptors, for example, inflammatory conditions.
Type:
Grant
Filed:
June 25, 1998
Date of Patent:
April 27, 2010
Assignee:
Promics Pty Limited
Inventors:
David Fairlie, Stephen Maxwell Taylor, Angela Monique Finch, Allan Wong
Abstract: It has now been discovered that GLP-1 treatment after acute stroke or hemorrhage, preferably intravenous administration, can be an ideal treatment because it provides a means for optimizing insulin secretion, increasing brain anabolism, enhancing insulin effectiveness by suppressing glucagon, and maintaining euglycemia or mild hypoglycemia with no risk of severe hypoglycemia.